Börse von finanzen.net | Aktien-Nachrichten | Marktberichte

DAX	6.050	-3,4%	Dow	12.119	-2,2%	Euro	1,2432	0,6%
ESt50	2.069	-2,4%	Nas	2.748	-2,8%	Öl	98,82	-2,8%
TDax	730,9	-2,7%	Nikkei	8.440	-1,2%	Gold	1.626	4,2%

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Depot
Times + Sales	Chart-Analyse	Analysen	Dividende/HV	Profil	Optionsscheine	Watchlist
Börsenplätze	Chartvergleich	Kursziele		Insidertrades	Knock-outs	myHome
Orderbuch	Realtime Stuttgart	RSS Feed	Analyse	im Forum	Fonds	Senden
Historisch	Realtime Push	myNews neu		IR-Daten	Anleihen	handeln

01.06.12	Combined Shareholders’ Meeting of IPSEN S.A. Held on 1 June 2012
21.05.12	600 Patients Recruited in Active Biotech’s and Ipsen’s tasquinimod Clinical Phase III Study
18.05.12	Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting
09.05.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company
04.05.12	Ipsen: Combined Shareholders’ Meeting of June 1, 2012
03.05.12	Ipsen's First Quarter 2012 Sales
26.04.12	Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders’ Meeting to be held on June 1, 2012
25.04.12	Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ)
17.04.12	Ipsen’s Partner, Inspiration Biopharmaceuticals, Announces US Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for the Treatment of Hemophilia B
06.04.12	IPSEN : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company

03.04.12	The 20th Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences Series: "Programmed Cells: from Basic Neuroscience to Therapy”
02.04.12	The Ipsen Group publishes its 2011 Registration document
05.03.12	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company
29.02.12	Ipsen’s 2011 Results and 2012 Objectives
24.02.12	Active Biotech and Ipsen Report Tasquinimod (TASQ) Phase II Long Term Safety Data at the 27th European Association of Urology (EAU) Congress
07.02.12	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company
02.02.12	Ipsen’s fourth quarter and full year 2011 sales and other significant developments
27.01.12	Ipsen Acknowledges Tanakan® Delisting in France
24.01.12	Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement
12.01.12	Half-Year IPSEN Liquidity Contract Statement Entered into With NATIXIS
05.01.12	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company
05.01.12	Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson's disease target
04.01.12	Ipsen announces its corporate agenda for 2012
06.12.11	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
06.12.11	PPG Announces Global Initiative to Leverage Titanium Dioxide Expertise
06.12.11	U.S. Bancorp Fund Services, LLC Launches Exchange Traded Funds Service, ETF-Fusion™
02.12.11	The 20th Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen is Awarded to Prof. Patricia K. Kuhl (University of Washington, Seattle, USA)
28.11.11	Ipsen’s partner Inspiration Biopharmaceuticals announces the initiation of the second phase III pivotal clinical study of OBI-1 in congenital hemophilia A with inhibitors
07.11.11	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
02.11.11	Rodman & Renshaw, LLC and Cowen and Company act as Exclusive Co-Placement Agents to Access Pharmaceuticals, Inc. in the Private Placement of $5.2 Million
02.11.11	Ipsen sells the North American1 development and marketing rights for Apokyn® to Britannia Pharmaceuticals, achieving a key milestone in the execution of its new North American strategy
27.10.11	Ipsen’s First Nine Months of 2011 Sales
20.10.11	Syntaxin and Ipsen Enter into a Strategic Agreement to Develop Novel Botulinum-toxin Therapeutics
20.10.11	Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
07.10.11	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company
03.10.11	Ipsen’s Partner, Inspiration Biopharmaceuticals, Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
27.09.11	Ipsen in-Licenses from Photocure Hexvix®, the First Approved & Marketed Drug for Improved Detection of Bladder Cancer, a Key Step in the Surgical Resection
05.09.11	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company
30.08.11	Ipsen's half-year 2011 Results
30.08.11	Inspiration Biopharmaceuticals and Ipsen Expand their Partnership in Preparation for the Commercial Launch of Inspiration’s Hemophilia Pipeline in Europe

Finanzen.net

IpsenAct Aktie [WKN: A0ESMG / ISIN: FR0010259150]

Hinweis

Newssuche

ALLE Nachrichten zur IpsenAct

Anzeige

ANZEIGE